Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Management of seasonal allergic conjunctivitis: guide to therapy.

Bielory BP, O'Brien TP, Bielory L.

Acta Ophthalmol. 2012 Aug;90(5):399-407. doi: 10.1111/j.1755-3768.2011.02272.x. Epub 2011 Nov 8. Review.

2.

Treatment of ocular inflammatory conditions with loteprednol etabonate.

Pavesio CE, Decory HH.

Br J Ophthalmol. 2008 Apr;92(4):455-9. doi: 10.1136/bjo.2007.132621. Epub 2008 Feb 1. Review.

PMID:
18245274
3.

A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis.

Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD, Hart K.

J Allergy Clin Immunol. 1998 Aug;102(2):251-5.

PMID:
9723669
4.

Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.

Gong L, Sun X, Qu J, Wang L, Zhang M, Zhang H, Wang L, Gu Y, Elion-Mboussa A, Roy L, Zhu B.

Clin Ther. 2012 Jun;34(6):1259-1272.e1. doi: 10.1016/j.clinthera.2012.04.024. Epub 2012 May 23.

PMID:
22627057
5.

A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.

Shulman DG, Lothringer LL, Rubin JM, Briggs RB, Howes J, Novack GD, Hart K.

Ophthalmology. 1999 Feb;106(2):362-9.

PMID:
9951491
6.

Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis.

Bielory BP, Perez VL, Bielory L.

Curr Opin Allergy Clin Immunol. 2010 Oct;10(5):469-77. doi: 10.1097/ACI.0b013e32833dfa28. Review.

PMID:
20720489
8.

Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate.

Comstock TL, Decory HH.

Int J Inflam. 2012;2012:789623. doi: 10.1155/2012/789623. Epub 2012 Mar 28.

9.

Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.

Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M.

Eye Contact Lens. 2004 Jan;30(1):10-3.

PMID:
14722462
11.

Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens.

Comstock TL, Holland EJ.

Expert Opin Pharmacother. 2010 Apr;11(5):843-52. doi: 10.1517/14656561003667532. Review.

PMID:
20210687
12.

Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis.

Bielory L, Lien KW, Bigelsen S.

Drugs. 2005;65(2):215-28. Review.

PMID:
15631542
13.

Fluticasone furoate nasal spray consistently and significantly improves both the nasal and ocular symptoms of seasonal allergic rhinitis: a review of the clinical data.

Scadding GK, Keith PK.

Expert Opin Pharmacother. 2008 Oct;9(15):2707-15. doi: 10.1517/14656566.9.15.2707 . Review.

PMID:
18803457
14.

[Seasonal and perennial allergic rhinoconjunctivitis].

Schröder K, Finis D, Meller S, Buhren BA, Wagenmann M, Geerling G.

Klin Monbl Augenheilkd. 2014 May;231(5):496-504. doi: 10.1055/s-0034-1368397. Epub 2014 May 5. Review. German.

PMID:
24799168
15.

Loteprednol etabonate: a review of ophthalmic clinical studies.

Howes JF.

Pharmazie. 2000 Mar;55(3):178-83. Review.

PMID:
10756536
16.

Intranasal corticosteroids and allergic rhinoconjunctivitis.

Origlieri C, Bielory L.

Curr Opin Allergy Clin Immunol. 2008 Oct;8(5):450-6. doi: 10.1097/ACI.0b013e32830d8501. Review.

PMID:
18769200
17.
19.

The current and future therapy of allergic conjunctivitis.

Friedlaender MH.

Curr Opin Ophthalmol. 1998 Aug;9(4):54-8. Review.

PMID:
10387470
20.

Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.

Amon M, Busin M.

Int Ophthalmol. 2012 Oct;32(5):507-17. Epub 2012 Jun 16. Review.

Items per page

Supplemental Content

Write to the Help Desk